Cytokinetics Opens Phase IIa Clinical Trial Of CK-2017357 For Patients With ALS

Cytokinetics Inc announced that it has opened a Phase IIa “Evidence of Effect” or EoE clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis or ALS

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail